A citation-based method for searching scientific literature

Luigi Della Corte, Virginia Foreste, Claudia Di Filippo, Pierluigi Giampaolino, Giuseppe Bifulco. Expert Opin Investig Drugs 2021
Times Cited: 4







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
50



The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Andrew J Wilson, Edward Holson, Florence Wagner, Yan-Ling Zhang, Daniel M Fass, Stephen J Haggarty, Srividya Bhaskara, Scott W Hiebert, Stuart L Schreiber, Dineo Khabele. Cancer Biol Ther 2011
37
25

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Andrew J Wilson, Matthew Stubbs, Phillip Liu, Bruce Ruggeri, Dineo Khabele. Gynecol Oncol 2018
55
25

Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Nicole Kiweler, Désirée Wünsch, Matthias Wirth, Nisintha Mahendrarajah, Günter Schneider, Roland H Stauber, Walburgis Brenner, Falk Butter, Oliver H Krämer. J Cancer Res Clin Oncol 2020
15
25

Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine Fuh, Mary Mullen, Barbara Blachut, Elizabeth Stover, Panagiotis Konstantinopoulos, Joyce Liu, Ursula Matulonis, Dineo Khabele, Nima Mosammaparast, Alessandro Vindigni. Gynecol Oncol 2020
14
25

DNA Fiber Analysis: Mind the Gap!
Annabel Quinet, Denisse Carvajal-Maldonado, Delphine Lemacon, Alessandro Vindigni. Methods Enzymol 2017
61
25

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
25

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V Kossenkov, Andrew J Wilson, Fiona Simpkins, David Speicher, Dineo Khabele,[...]. Cell Rep 2017
81
25

Alkaline Comet Assay for Assessing DNA Damage in Individual Cells.
Xinzhu Pu, Zemin Wang, James E Klaunig. Curr Protoc Toxicol 2015
43
25

Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Alison M Karst, Paul M Jones, Natalie Vena, Azra H Ligon, Joyce F Liu, Michelle S Hirsch, Dariush Etemadmoghadam, David D L Bowtell, Ronny Drapkin. Cancer Res 2014
93
25

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021
28
25


Replication Gaps Underlie BRCA Deficiency and Therapy Response.
Nicholas J Panzarino, John J Krais, Ke Cong, Min Peng, Michelle Mosqueda, Sumeet U Nayak, Samuel M Bond, Jennifer A Calvo, Mihir B Doshi, Matt Bere,[...]. Cancer Res 2021
30
25

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
743
25

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
25

Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
Chiara Conti, Elisabetta Leo, Gabriel S Eichler, Olivier Sordet, Melvenia M Martin, Angela Fan, Mirit I Aladjem, Yves Pommier. Cancer Res 2010
122
25

Synthetic lethality between CCNE1 amplification and loss of BRCA1.
Dariush Etemadmoghadam, Barbara A Weir, George Au-Yeung, Kathryn Alsop, Gillian Mitchell, Joshy George, Sally Davis, Alan D D'Andrea, Kaylene Simpson, William C Hahn,[...]. Proc Natl Acad Sci U S A 2013
132
25

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Jan J Bandolik, Alexandra Hamacher, Christian Schrenk, Robin Weishaupt, Matthias U Kassack. Int J Mol Sci 2019
17
25

Perturbing cohesin dynamics drives MRE11 nuclease-dependent replication fork slowing.
Denisse Carvajal-Maldonado, Andrea K Byrum, Jessica Jackson, Sarah Wessel, Delphine Lemaçon, Laure Guitton-Sert, Annabel Quinet, Stephanie Tirman, Simona Graziano, Jean-Yves Masson,[...]. Nucleic Acids Res 2019
25
25

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Ann-Gerd Thorsell, Torun Ekblad, Tobias Karlberg, Mirjam Löw, Ana Filipa Pinto, Lionel Trésaugues, Martin Moche, Michael S Cohen, Herwig Schüler. J Med Chem 2017
159
25


Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Andrew J Wilson, Jeanette Saskowski, Whitney Barham, Dineo Khabele, Fiona Yull. Mol Cancer 2015
22
25

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
Stephanie Wurster, Fabian Hennes, Ann C Parplys, Jasna I Seelbach, Wael Y Mansour, Alexandra Zielinski, Cordula Petersen, Till S Clauditz, Adrian Münscher, Anna A Friedl,[...]. Oncotarget 2016
33
25

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
55
25

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Panagiotis A Konstantinopoulos, Andrew J Wilson, Jeanette Saskowski, Erica Wass, Dineo Khabele. Gynecol Oncol 2014
73
25

Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.
Jeff Hirst, Harsh B Pathak, Stephen Hyter, Ziyan Y Pessetto, Thuc Ly, Stefan Graw, Devin C Koestler, Adam J Krieg, Katherine F Roby, Andrew K Godwin. Cancer Res 2018
25
25


Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.
Sonia Iyer, Shuang Zhang, Simge Yucel, Heiko Horn, Sean G Smith, Ferenc Reinhardt, Esmee Hoefsmit, Bimarzhan Assatova, Julia Casado, Marie-Charlotte Meinsohn,[...]. Cancer Discov 2021
18
25

Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.
Andrew J Wilson, Anum S Lalani, Erika Wass, Jeanette Saskowski, Dineo Khabele. Gynecol Oncol 2012
29
25

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
324
25

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Shariska Petersen, Andrew J Wilson, Jeff Hirst, Katherine F Roby, Oluwole Fadare, Marta A Crispens, Alicia Beeghly-Fadiel, Dineo Khabele. Gynecol Oncol 2020
13
25



In vivo pharmacodynamic imaging of proteasome inhibition.
Erin A Kimbrel, Tina N Davis, James E Bradner, Andrew L Kung. Mol Imaging 2009
37
25

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Ailsa J Frew, Ricky W Johnstone, Jessica E Bolden. Cancer Lett 2009
184
25

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Andrew J Wilson, Jeanette Saskowski, Whitney Barham, Fiona Yull, Dineo Khabele. J Ovarian Res 2015
32
25

Hdac3 is essential for the maintenance of chromatin structure and genome stability.
Srividya Bhaskara, Sarah K Knutson, Guochun Jiang, Mahesh B Chandrasekharan, Andrew J Wilson, Siyuan Zheng, Ashwini Yenamandra, Kimberly Locke, Jia-Ling Yuan, Alyssa R Bonine-Summers,[...]. Cancer Cell 2010
247
25

Association of BRCA1 with Rad51 in mitotic and meiotic cells.
R Scully, J Chen, A Plug, Y Xiao, D Weaver, J Feunteun, T Ashley, D M Livingston. Cell 1997
25


PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu,[...]. Mol Cancer 2020
65
25

Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Pepijn M Schoonen, Yannick P Kok, Elles Wierenga, Bjorn Bakker, Floris Foijer, Diana C J Spierings, Marcel A T M van Vugt. Mol Oncol 2019
31
25

Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
Chloe Camille Lepage, Michaela Cora Lynn Palmer, Ally Catherina Farrell, Nicole Marie Neudorf, Zelda Lichtensztejn, Mark William Nachtigal, Kirk James McManus. Br J Cancer 2021
11
25

Homologous recombination deficiency and ovarian cancer.
Jonathan A Ledermann, Yvette Drew, Rebecca S Kristeleit. Eur J Cancer 2016
110
25

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Charlie Gourley, Judith Balmaña, Jonathan A Ledermann, Violeta Serra, Rebecca Dent, Sibylle Loibl, Eric Pujade-Lauraine, Simon J Boulton. J Clin Oncol 2019
69
25

Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Andrew J Wilson, Kofi Sarfo-Kantanka, Toby Barrack, Alexandra Steck, Jeanette Saskowski, Marta A Crispens, Dineo Khabele. Gynecol Oncol 2016
21
25

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control.
Srividya Bhaskara, Brenda J Chyla, Joseph M Amann, Sarah K Knutson, David Cortez, Zu-Wen Sun, Scott W Hiebert. Mol Cell 2008
252
25

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
Panagiotis A Konstantinopoulos, Ursula A Matulonis. Hematol Oncol Clin North Am 2018
14
25

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.